Spyre Therapeutics grants stock options to non-executive employees as part of equity inducement awards under its 2018 Plan.
Quiver AI Summary
Spyre Therapeutics, Inc. announced that its Compensation Committee approved the grant of stock options to purchase a total of 51,300 shares of common stock to four non-executive employees as part of the 2018 Equity Inducement Plan. This decision, made on June 1, 2026, was significant for the employees' acceptance of their roles and complies with Nasdaq regulations. The options have a 10-year term with an exercise price corresponding to Spyre's stock closing price of $70.54 on that date. Vesting occurs gradually, with one-fourth available after one year and the remainder vesting monthly thereafter, conditional on continued employment. Spyre Therapeutics focuses on developing advanced immunology therapies that improve disease management and patient experience.
Potential Positives
- Approval of stock options for non-executive employees may enhance talent acquisition and retention, signaling the company's commitment to attracting skilled professionals.
- The grant of stock options aligns employee interests with company performance, potentially motivating employees to contribute to long-term success.
- The stock options have a 10-year term, providing employees with a significant timeframe to benefit from potential company growth.
- The decision to grant these options reflects compliance with Nasdaq Listing Rule 5635, ensuring the company adheres to regulatory standards, which may enhance investor confidence.
Potential Negatives
- The grant of stock options to non-executive employees may raise concerns about the company's financial management and priorities, especially if perceived as excessive compensation during a clinical-stage phase.
- The reliance on equity inducement awards for attracting talent may indicate difficulties in recruiting or retaining skilled employees, potentially signaling instability within the company.
- The vesting schedule of the stock options ties employee incentives to the company's stock performance, which could amplify investor concerns about stock volatility or performance in the long term.
FAQ
What stock options did Spyre Therapeutics grant?
Spyre granted stock options to purchase 51,300 shares to four non-executive employees as equity inducement awards.
What is the exercise price of the stock options?
The exercise price of the stock options is $70.54, equal to the closing price on June 1, 2026.
What are the vesting terms for the stock options?
The options vest 1/4th on the first anniversary and 1/48th monthly thereafter, subject to continuous service.
Under which plan were the stock options granted?
The stock options were granted under the Spyre Therapeutics, Inc. 2018 Equity Inducement Plan, as amended.
Who should investors contact for more information?
Investors can contact Eric McIntyre, SVP of Finance and Investor Relations, at [email protected].
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$SYRE Insider Trading Activity
$SYRE insiders have traded $SYRE stock on the open market 35 times in the past 6 months. Of those trades, 0 have been purchases and 35 have been sales.
Here’s a breakdown of recent trading of $SYRE stock by insiders over the last 6 months:
- SHELDON SLOAN (Chief Medical Officer) has made 0 purchases and 9 sales selling 94,624 shares for an estimated $6,623,576.
- CAMERON TURTLE (Chief Executive Officer) has made 0 purchases and 18 sales selling 90,000 shares for an estimated $4,451,950.
- SCOTT L BURROWS (Chief Financial Officer) has made 0 purchases and 8 sales selling 30,000 shares for an estimated $1,896,757.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$SYRE Hedge Fund Activity
We have seen 119 institutional investors add shares of $SYRE stock to their portfolio, and 71 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- PERCEPTIVE ADVISORS LLC added 1,839,780 shares (+149.6%) to their portfolio in Q4 2025, for an estimated $60,271,192
- JANUS HENDERSON GROUP PLC added 1,816,009 shares (+13969.3%) to their portfolio in Q4 2025, for an estimated $59,492,454
- CAPITAL INTERNATIONAL INVESTORS removed 1,746,412 shares (-50.0%) from their portfolio in Q1 2026, for an estimated $88,089,021
- JEFFERIES FINANCIAL GROUP INC. removed 1,388,854 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $45,498,857
- TANG CAPITAL MANAGEMENT LLC removed 1,307,800 shares (-40.9%) from their portfolio in Q4 2025, for an estimated $42,843,528
- VR ADVISER, LLC added 1,000,000 shares (+37.2%) to their portfolio in Q4 2025, for an estimated $32,759,999
- VANGUARD GROUP INC added 984,344 shares (+32.3%) to their portfolio in Q4 2025, for an estimated $32,247,109
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
$SYRE Analyst Ratings
Wall Street analysts have issued reports on $SYRE in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Deutsche Bank issued a "Buy" rating on 06/04/2026
- Mizuho issued a "Outperform" rating on 12/18/2025
To track analyst ratings and price targets for $SYRE, check out Quiver Quantitative's $SYRE forecast page.
$SYRE Price Targets
Multiple analysts have issued price targets for $SYRE recently. We have seen 12 analysts offer price targets for $SYRE in the last 6 months, with a median target of $92.5.
Here are some recent targets:
- David Hoang from Deutsche Bank set a target price of $115.0 on 06/04/2026
- Alex Thompson from Stifel set a target price of $107.0 on 05/06/2026
- Samantha Semenkow from Citigroup set a target price of $97.0 on 05/06/2026
- Debanjana Chatterjee from Jones Trading set a target price of $95.0 on 04/17/2026
- Colleen Kusy from Baird set a target price of $90.0 on 04/14/2026
- Martin Auster from Raymond James set a target price of $80.0 on 04/14/2026
- David Nierengarten from Wedbush set a target price of $80.0 on 04/14/2026
Full Release
WALTHAM, Mass., June 05, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Company” or “Spyre”), a clinical-stage biotechnology company committed to developing next-generation therapies that elevate the standard in immunology by delivering more complete disease control, greater durability, and a simpler treatment experience for patients, today announced that Spyre’s independent Compensation Committee of the Board of Directors approved the grant of stock options to purchase an aggregate of 51,300 shares of common stock of Spyre to four non-executive employees as equity inducement awards under the Spyre Therapeutics, Inc. 2018 Equity Inducement Plan, as amended (the “2018 Plan”). The stock options were approved on June 1, 2026 and were material to each employee's acceptance of employment with Spyre, in accordance with Nasdaq Listing Rule 5635(c)(4).
The stock options were granted with a 10-year term and an exercise price equal to $70.54, the closing price per share of Spyre's common stock as reported by Nasdaq on June 1, 2026. The options granted to the employees shall vest and become exercisable as to one-fourth (1/4th) of the shares subject to the respective options on the first anniversary of the employee’s start date, and one-forty-eighth (1/48th) of the shares subject to the respective options shall vest and become exercisable monthly thereafter, in each case, subject to continuous service with Spyre through the applicable vesting dates. The stock options are subject to the terms of the 2018 Plan.
About Spyre Therapeutics
Spyre Therapeutics is a clinical-stage biotechnology company committed to developing next-generation therapies that elevate the standard in immunology by delivering more complete disease control, greater durability, and a simpler treatment experience for patients. Spyre's pipeline includes investigational extended half-life antibodies targeting α4β7, TL1A, and IL-23.
For more information, please visit http://spyre.com.
For Investors
:
Eric McIntyre
SVP of Finance and Investor Relations
Spyre Therapeutics
[email protected]
